Masimo Corporation (MASI) has a MoatMap StockRank of 90/100 based on Quality (78/100), Value (25/100), and Momentum (74/100) factor scores. The current signal is STRONG BUY. Masimo possesses a high-quality core non-invasive monitoring business with strong moats, but ongoing corporate governance battles, activist pressure, and the complex spin-off of its consumer audio business distract from the core investment thesis.
Masimo Corporation is a global medical technology company developing and manufacturing innovative noninvasive patient monitoring technologies, including pulse oximetry, capnography, and brain function monitoring. The company's competitive moat is built on its patented "Measure-through Motion and Low Perfusion" technology, which significantly improves accuracy in challenging clinical conditions. Its commitment to R&D and a broad portfolio of advanced monitoring solutions position it as a leader in patient safety and clinical decision support.
| Price | $179.95 |
| Market Cap | $9.3B |
| P/E (TTM) | 44.28 |
| P/E (Forward) | 27.10 |
| Price/Book | 11.88 |
| Return on Equity | 25.0% |
| Return on Invested Capital | 23.0% |
| Debt/Equity | 61.59 |
| Gross Margin | 61.6% |
| Operating Margin | 23.6% |
| Revenue Growth | 8.5% |
| Free Cash Flow | $328M |
Masimo Corporation operates in the Medical Devices industry, part of the Healthcare sector (United States).